Literature DB >> 11973240

Validity of the time trade-off and standard gamble methods of utility assessment in retinal patients.

S Sharma1, G C Brown, M M Brown, H Hollands, R Robins, G K Shah.   

Abstract

AIM: To assess the validity of the time trade-off (TTO) and standard reference gamble (SRG) techniques of utility assessment in patients with retinal disease. A cross section of eligible patients was studied and validity was determined through their relation with two logical constructs, visual acuity and scores from the Visual Function 14 (VF-14) index.
METHODS: The study consisted of eligible patients presenting to a tertiary retinal facility who completed an interview. All patients had best corrected vision of 20/40 or worse in at least one eye. TTO and SRG utilities, as well as a VF-14 questionnaire, were administered through a standardised interview. Demographic and clinical (including Snellen visual acuity) information was also collected.
RESULTS: 323 patients met these study criteria. Significant predictors of TTO utilities in the multivariate analysis were vision in the better seeing eye (p<0.01) and VF-14 scores (p<0.01). Significant predictors of standard gamble utilities were also vision in the better seeing eye (p<0.01) and VF-14 scores (p<0.05).
CONCLUSION: Both the standard gamble and TTO methods demonstrate strong validity when evaluated against visual acuity in the better seeing eye and the VF-14 score.

Entities:  

Mesh:

Year:  2002        PMID: 11973240      PMCID: PMC1771136          DOI: 10.1136/bjo.86.5.493

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  13 in total

1.  Cost-effectiveness of treatment for threshold retinopathy of prematurity.

Authors:  G C Brown; M M Brown; S Sharma; W Tasman; H C Brown
Journal:  Pediatrics       Date:  1999-10       Impact factor: 7.124

2.  The cost-effectiveness of grid laser photocoagulation for the treatment of diabetic macular edema: results of a patient-based cost-utility analysis.

Authors:  S Sharma; G C Brown; M M Brown; H Hollands; G K Shah
Journal:  Curr Opin Ophthalmol       Date:  2000-06       Impact factor: 3.761

3.  Utilities and quality-adjusted life years.

Authors:  G W Torrance; D Feeny
Journal:  Int J Technol Assess Health Care       Date:  1989       Impact factor: 2.188

4.  Utility values and age-related macular degeneration.

Authors:  G C Brown; S Sharma; M M Brown; J Kistler
Journal:  Arch Ophthalmol       Date:  2000-01

5.  Incremental cost-effectiveness of laser therapy for choroidal neovascularization associated with histoplasmosis.

Authors:  G C Brown; M M Brown; S Sharma; B Busbee; H Brown
Journal:  Retina       Date:  2000       Impact factor: 4.256

6.  Converting visual acuity to utilities.

Authors:  S Sharma; G C Brown; M M Brown; G K Shah; K Snow; H Brown; H Hollands
Journal:  Can J Ophthalmol       Date:  2000-08       Impact factor: 1.882

7.  Incremental cost effectiveness of laser photocoagulation for subfoveal choroidal neovascularization.

Authors:  G C Brown; M M Brown; S Sharma; H Brown; W Tasman
Journal:  Ophthalmology       Date:  2000-07       Impact factor: 12.079

8.  Validity of the visual function index (VF-14) in patients with retinal disease.

Authors:  M Linder; T S Chang; I U Scott; D Hay; K Chambers; L M Sibley; E Weis
Journal:  Arch Ophthalmol       Date:  1999-12

9.  The VF-14. An index of functional impairment in patients with cataract.

Authors:  E P Steinberg; J M Tielsch; O D Schein; J C Javitt; P Sharkey; S D Cassard; M W Legro; M Diener-West; E B Bass; A M Damiano
Journal:  Arch Ophthalmol       Date:  1994-05

Review 10.  Measuring health-related quality of life.

Authors:  G H Guyatt; D H Feeny; D L Patrick
Journal:  Ann Intern Med       Date:  1993-04-15       Impact factor: 25.391

View more
  21 in total

Review 1.  Cost-Effectiveness Models in Age-Related Macular Degeneration: Issues and Challenges.

Authors:  Jordana K Schmier; Carolyn K Hulme-Lowe
Journal:  Pharmacoeconomics       Date:  2016-03       Impact factor: 4.981

2.  Value based medicine.

Authors:  S M Kymes; K D Frick
Journal:  Br J Ophthalmol       Date:  2005-05       Impact factor: 4.638

Review 3.  [Value-based medicine in ophthalmology].

Authors:  C Hirneiss; A S Neubauer; C Tribus; A Kampik
Journal:  Ophthalmologe       Date:  2006-06       Impact factor: 1.059

4.  Quality of life and relative importance: a comparison of time trade-off and conjoint analysis methods in patients with age-related macular degeneration.

Authors:  P A Aspinall; A R Hill; B Dhillon; A M Armbrecht; P Nelson; C Lumsden; E Farini-Hudson; R Brice; A Vickers; P Buchholz
Journal:  Br J Ophthalmol       Date:  2007-01-17       Impact factor: 4.638

5.  Comment on the value of vision by Knauer et al..

Authors:  George L Spaeth
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-02-17       Impact factor: 3.117

6.  The impact of persistent visually disabling vitreous floaters on health status utility values.

Authors:  Haidong Zou; Haiyun Liu; Xun Xu; Xi Zhang
Journal:  Qual Life Res       Date:  2012-10-11       Impact factor: 4.147

7.  Cost-effectiveness of cataract surgery in Japan.

Authors: 
Journal:  Jpn J Ophthalmol       Date:  2011-06-22       Impact factor: 2.447

8.  Validity of EuroQOL-5D, time trade-off, and standard gamble for age-related macular degeneration in the Singapore population.

Authors:  K G Au Eong; E W Chan; N Luo; S H Wong; N W H Tan; T H Lim; A M Wagle
Journal:  Eye (Lond)       Date:  2012-01-06       Impact factor: 3.775

9.  Cost-utility analysis of cataract surgery in Japan: a probabilistic Markov modeling study.

Authors:  Yoshimune Hiratsuka; Masakazu Yamada; Yoko Akune; Akira Murakami; Annabelle A Okada; Hidetoshi Yamashita; Yuichi Ohashi; Naoya Yamagishi; Hiroshi Tamura; Shunichi Fukuhara; Tomoyuki Takura
Journal:  Jpn J Ophthalmol       Date:  2013-04-16       Impact factor: 2.447

Review 10.  The value of vision.

Authors:  Christine Knauer; Norbert Pfeiffer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-12-11       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.